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Abstract 
Background:  The National Institute for Health and Care Excellence (NICE) published NG12 
in 2015. The referral criteria for suspected colorectal cancer (CRC) caused controversy, 
because tests for occult blood in faeces were recommended. Faecal immunochemical tests 
for haemoglobin (FIT), which estimate faecal haemoglobin concentrations (f-Hb), might more 
than fulfil the intentions. Our aim was to compare the utility of f-Hb as the initial 
investigation with the NICE NG12 symptom-based guidelines. 
Methods:  Data from three studies were included. Patients had sex, age, symptoms, f-Hb 
and colonoscopy and histology data recorded. Sensitivity, specificity, positive (PPV) and 
negative predictive value (NPV) of f-Hb and NG12 were calculated for all significant colorectal 
disease (SCD: CRC, higher-risk adenoma and inflammatory bowel disease).  Overall 
diagnostic accuracy was also estimated by the area under the receiver operating characteristic 
curve (AUC). 
Results:  1514 patients were included. At a cut-off of >10 µg Hb/g faeces, the sensitivity of 
f-Hb for CRC was 93.3% (95% confidence interval (CI): 80.7-98.3) with NPV of 99.7% (95%CI: 
99.2-99.9). The sensitivity and NPV for SCD were 63.2% (95%CI: 56.6-69.4) and 96.0% 
(95%CI: 91.4-94.4) respectively. The NG12 sensitivity and NPV for SCD were 58.4% (95%CI: 
51.8-64.8) and 87.6% (95%CI: 85.0-89.8) respectively. The AUC for CRC was 0.85 (95% CI 
0.87-0.90) for f-Hb versus 0.65 (95%CI 0.58-0.73) for NG12 (p<0.005). For SCD, the AUC 
was 0.73 (95%CI: 0.69-0.77) for f-Hb versus 0.56 (95%CI: 0.52-0.60) for NG12 (p<0.0005). 
Conclusion: f-Hb provides a good rule-out test for SCD and has significantly higher 
overall diagnostic accuracy than NG12. 
 
  
Introduction 
Colorectal cancer (CRC) is the second most common cause of cancer related death in the 
UK, accounting for  about 10% of all such deaths.1 Patients with CRC may present with various 
lower gastrointestinal (GI) symptoms, such as change in bowel habit, rectal bleeding, lower 
abdominal pain, abdominal mass, anaemia, or unexplained weight loss. These symptoms are 
sometimes referred to as “alarm” or “red flag” symptoms and, in a patient who reports any of 
these, urgent referral for lower GI endoscopy to exclude CRC is usual current practice. 
However, such symptoms are also common in patients with non-malignant lower GI disease 
and, as a result, their diagnostic accuracy for CRC has been demonstrated to be poor.2,,3 
Referral guidelines for suspected cancer were published for the National Health Service in 
England in 2011 (CG27)4 and subsequently in 2015 (NG12) by the National Institute for Health 
and Care Excellence (NICE).5 Current NG12 criteria that should stimulate urgent referral are 
listed in Table 1. The older NICE CG27 guideline has been the most widely used and 
evaluated referral guidance, but has a low specificity and variable sensitivity,6 and it was 
recognised that symptoms have a poor positive predictive value (PPV) for CRC of only 3–4%.4 
A detailed review and meta-analysis also concluded that symptoms alone are poor predictors 
of underlying pathology.3 Further, although risk prediction models which combine multiple risk 
factors and symptoms might have the potential to improve timely diagnosis,7 many patients 
continue to be referred to secondary care for investigation in the absence of any reliable first-
line predictor of significant colorectal disease (SCD), namely CRC plus higher-risk adenoma 
(HRA)8 plus inflammatory bowel disease (IBD: Crohn’s disease and ulcerative colitis). 
NICE published NG12 in June 2015.5 These guidelines caused much controversy when 
published in both draft and final formats. In particular, the recommendation of a “test for occult 
blood in faeces”, which was initially interpreted by most as a recommendation for the 
traditional guaiac-based faecal occult blood test (gFOBT), was very controversial and became 
the subject of some concern and debate.9-11 Previously published authoritative guidelines from 
NICE, the Scottish Intercollegiate Guidelines Network (SIGN) and the British Society of 
Gastroenterology (BSG) did state that there was no role for such gFOBT in assessment of 
patients presenting in primary care with lower GI symptoms, or in the investigation of iron 
deficiency anaemia.12 In consequence, gFOBT were eliminated from the repertoires of many 
laboratories and its use in clinical settings other than screening very much discouraged.12 
Indeed, NICE did note that the new 2015 NG12 recommendation to test for occult blood in 
faeces in patients at low risk of CRC would necessitate a change in practice, because such 
tests were not currently available.5 However, realisation quickly grew that faecal 
immunochemical tests for haemoglobin (FIT), which are able to quantitate faecal haemoglobin 
concentrations (f-Hb), could well more than fulfil the intentions of NG12.10  It was recognised 
by NICE that some evidence did exist to suggest that FIT might have applicability in triaging 
patients presenting in primary care.9 FIT, a newer type of test for the detection of occult blood 
in faeces, use antibodies specific to human haemoglobin. They have been developed as a 
significant improvement on gFOBT, which are based on the pseudo-peroxidase activity of the 
haem component of haemoglobin and produce a blue colour change on the test card if 
positive. Sometimes, this colour change occurs because of moieties with peroxidase activity 
in the diet, or with medicines being taken, leading to false positive test results. Because FIT 
are designed to specifically detect human haemoglobin, they do not suffer from interference 
from dietary constituents. Moreover, FIT target the globin component of haemoglobin, which 
degrades as it travels through the GI tract, so FIT are less likely to detect globin from upper 
GI bleeding.13 In addition, FIT are analytically much more sensitive than gFOBT and so detect 
smaller amounts of blood in faeces. 
There is now significant evidence that FIT do have applicability as the initial approach to the 
assessment of symptomatic patients presenting in primary care, including those who warrant 
urgent referral. It has been shown that use of f-Hb performs better than previous high-risk 
symptom-based strategies from NICE and SIGN for fast-tracking suspected CRC 
referrals.6,12,14-19 Moreover and, most importantly, f-Hb with very low cut-off concentration has 
very high NPV for the detection of SCD in this clinical setting.10 In consequence, a “negative” 
test result provides considerable reassurance that referral for colonoscopy is not required 
urgently or even at all. There is no doubt that f-Hb measurements have considerable potential 
to contribute to reducing unnecessary colonoscopy for the majority of symptomatic patients. 
However, the question remains of whether f-Hb, a laboratory-based investigation, is better 
than the recent NG12 symptom-based referral guidelines as the initial approach in primary 
care to rule in CRC (the purpose of NG12) or rule out SCD. We did not aim to examine 
the diagnostic accuracy of the groups detailed in NG12 as shown in Table 1 since this 
was comprehensively documented in the guideline.5 The aim of this study was to 
undertake such a comparison, particularly investigating sensitivity as a measure of 
goodness as a rule in test and NPV as a good estimate of utility as rule out test, for both 
CRC and SCD. 
Methods 
Data from three studies conducted in Scotland were included in our analysis; these are 
described in detail in the relevant peer-reviewed publications, and are summarised below.17-
19 The studies, on the role of f-Hb in assessment of patients presenting in primary care with 
lower GI symptoms, were conducted between 2010 and 2015 and included only patients with 
sex, age, details of symptoms leading to referral for lower GI endoscopy, f-Hb and 
complete colonoscopy data with histology where applicable. The referrals were done 
as described in the publications and did not follow the NG12 criteria. Reasons for referral 
were based on symptoms including rectal bleeding, change in bowel habit, iron deficiency 
anaemia, abdominal pain, bloating, polyp/colorectal cancer surveillance, family history and 
assessment of IBD. A f-Hb of greater >10 µg Hb/g faeces was deemed a positive test result. 
Results were collated from the three study databases. Referral symptoms were reviewed and 
categorised as in keeping with NG12 referral criteria or not.  
Study one (FITS)17 was an investigation on diagnostic accuracy based on a consecutive series 
of participants; no intervention was made based on the f-Hb concentration. Patients who had 
been referred from primary care for endoscopic examination of the lower GI tract in NHS 
Tayside from February 2010 to March 2012 were invited by a colorectal specialist research 
nurse to participate in the study by completing a single sample faecal collection for f-Hb. The 
returned samples were analysed for f-Hb using one of two OC-Sensor Diana automated 
immunoturbidimetric analysers (Eiken Chemical Co., Ltd, Tokyo, Japan). Analyses were 
carried out in the Scottish Bowel Screening Centre Laboratory.  
Study two (FITS2)19 aimed to determine whether patients with lower abdominal symptoms can 
be investigated quickly using results of f-Hb and whether this investigation could form part of 
a diagnostic pathway for SCD. Participants referred from primary care for colonoscopy in NHS 
Lanarkshire from June 2013 to December 2013 inclusive were recruited by sending one faecal 
specimen collection device with the appointment for endoscopy and the bowel cleansing 
materials. The returned samples were analysed for f-Hb using one HM-JACKarc analyser 
(Kyowa-Medex Co., Ltd., Tokyo, Japan).  
Study three (FITS+)18 assessed the diagnostic accuracies of quantitative f-Hb and faecal 
calprotectin tests in patients presenting to primary care with lower GI symptoms who were 
then referred for investigation. All adult patients referred in NHS Tayside over a six-month 
period from October 2013 to March 2014 were eligible. Estimates of f-Hb were generated 
using one OC-Sensor io analyser (Eiken Chemical Co., Ltd., Tokyo, Japan). 
Statistical Analysis 
To determine differences in clinical performance between f-Hb and NG12 referral criteria as 
an initial investigation, we performed the following analyses. Sensitivity, specificity, PPV and 
NPV (all with 95%CI) were calculated using a cut-off of >10 g Hb/g faeces for CRC, HRA, 
advanced neoplasia (AN = CRC plus HRA), IBD and SCD. Receiver operating characteristic 
(ROC) curves for CRC and SCD were constructed and the area under the curve (AUC), with 
95%CI, was determined as a simple easy to understand estimate of overall diagnostic 
accuracy. AUC were calculated overall and separately for the three analytical systems used, 
for men and women and for those aged <50 years and >50 years. AUC were compared using 
VassarStats: Website for Statistical Computation (http://vassarstats.net/roc_comp.html). 
Associations between categorical variables were examined using chi-squared tests for linear 
trend unless otherwise specified. A p-value of <0.05 was considered statistically significant. 
Statistical analyses were performed using SPSS software (SPSS Inc., Chicago, IL, USA).  
Results 
Patient population 
1514 patients were included in our analysis. Patient sex and age, two variables proven to 
affect f-Hb,20 presenting symptoms, f-Hb and final diagnosis following investigation were 
recorded in the study specific databases: 280 patients were recruited to the FITS study, 484 
patients to FITS2 and 750 patients to FITS+. CRC was found in 45 patients (3.0%), HRA in 
95 (6.3%), AN in 140 (9.3%), IBD in 91 (6.0%) and SCD in 231 (15.3%). The number who 
would be directly referred in all three studies for colonoscopy following NG12 
guidelines was 731 (48.3%) and the number who would be referred for testing for occult 
blood in faeces was 485 (32.0%). The criterion used for a positive outcome from f-Hb in 
those who would have been referred for testing for occult blood using NG12 was f-Hb 
>10µg Hb/g faeces.  A total of 1216 (79.7%) would have a further action taken as a result 
of the NICE NG12 guidelines.  No gFOBT was done on the last three groups in Table 1 
in any of the three studies because the patient had been referred for endoscopy based 
solely on a priori clinical assessment in primary care and gFOBT were unavailable in 
both NHS Tayside and NHS Lanarkshire.  
Comparison of the three FIT analytical systems 
The three different FIT analytical systems were assessed cumulatively and as individual 
studies and a simple comparison undertaken using the AUC as a simple indicator of overall 
diagnostic accuracy. There was no observed differences between the OC-Sensor 
Diana, HM-JACKarc and the OC-Sensor io systems (Table 2). Specifically, the AUC for 
CRC were 0.87 (95%CI: 0.78-0.94), 0.89 (95%CI: 0.84-0.93) and 0.84 (95%CI: 0.77-0.91) for 
the three analysers respectively. The AUC for SCD were 0.73 (95%CI: 0.65-0.81), 0.73 
(95%CI: 0.65-0.81) and 0.73 (95%CI: 0.67-0.78) respectively.  
Clinical characteristics of faecal haemoglobin concentration (f-Hb) 
The sensitivity, specificity, PPV and NPV of f-Hb for CRC, HRA, AN, IBD and SCD are 
summarised in Table 3. The sensitivity, a good measure of the utility of the investigation 
as a rule in test, for CRC, HRA, AN, IBD and SCD was 93.3% (95%CI: 80.7-98.3), 50.5% 
(95%CI: 40.1-60.9), 64.3% (95%CI: 55.7-72.1), 61.5% (95%CI: 50.7-71.4) and 63.2% (95%CI: 
56.6-69.4) respectively. NPV, the most relevant characteristic to assess f-Hb as a rule out 
test was 99.7% (95%CI: 99.2-99.9), 95.9% (95%CI: 94.5-96.9), 95.6% (95%CI: 94.2-96.7), 
96.9% (95%CI: 95.7-97.8) and 93.1% (95%CI: 91.4-94.4) respectively. 
Clinical characteristics of f-Hb by sex 
Differences were observed in sensitivity, specificity, PPV and NPV between men and women, 
although the AUC was not significantly different in CRC, HRA, AN, IBD or SCD between the 
two groups (Table 3; p>0.05). Sensitivity for CRC, HRA, AN, IBD and SCD was higher in men 
than women and specificity lower. NPV was similar between men and women for CRC, HRA, 
AN, IBD and SCD. 
Clinical characteristics of f-Hb by age 
In those aged less than 50 years, the sensitivity for detecting CRC, HRA, AN, IBD and SCD 
was higher than in those older than 50 years. The NPV for CRC, HRA, AN, IBD and SCD 
were 100.0% (95%CI: 98.1-1.0), 97.6% (95%CI: 94.7-99.0), 97.6% (95%CI: 94.7-99.0), 95.3% 
(95%CI: 91.7-97.4) and 92.9% (95%CI: 88.8-95.6) respectively in those less than 50 years 
compared to 99.7% (95%CI: 96.0-98.3), 95.4% (95%CI: 93.7-96.6), 95.3% (95%CI: 93.3-
96.3), 97.4% (95%CI: 96.0-98.3) and 92.4% (95%CI: 90.4-94.0) respectively in those aged 
older than 50 years. The AUC for f-Hb was not significantly different for CRC, HRA, AN, IBD 
and SCD in those participants less than 50 years of age and in those equal to or older than 
50 years (Table 3; p>0.05). 
Overall diagnostic accuracy of f-Hb and NG12 compared 
Overall, f-Hb had statistically significantly higher diagnostic accuracy than NG12 for all 
of CRC, HRA, AN, IBD and SCD (p<0.0005) as shown in Table 3. For both CRC and SCD, 
the AUC was significantly higher for f-Hb than NG12 (p<0.0005).   
Number of cases missed using f-Hb and NG12 
As shown in Table 4, three cases of CRC would be potentially missed using f-Hb with a 
>10 µg Hb/g faeces cut-off. All three cases had detectable f-Hb, but with a concentration 
below the lower limit of the analytical working range as reported by the manufacturer 
of 10 µg Hb/g faeces, and were recruited to the FITS+ study. Two of these patients would 
have met the NG12 criteria. In contrast, 10 patients with CRC would be missed by NG12 
criteria of which nine had a positive f-Hb test result >10 µg Hb/g faeces. Use of f-Hb 
missed overall fewer cases of AN (50 v 53), IBD (35 v 43) and SCD (85 v 96) as compared 
to NG12.  
Discussion 
NG12 uses the terminology “a test for occult blood in faeces” and this could be 
interpreted as gFOBT or FIT: no studies such as ours have investigated gFOBT, an 
obsolete investigation,12 and no patient in any of the three studies from which data were 
obtained had gFOBT performed. Most importantly, the high NPV of f-Hb for all SCD 
confirm the high utility of f-Hb as a rule-out test. In addition, the results demonstrate 
that f-Hb with a cut-off for referral of >10 µg Hb/g faeces, a laboratory-based 
investigation, has significantly higher overall diagnostic accuracy than the symptom-
based NICE NG12 guidelines and would therefore be more reliable as an indication for 
referral for further investigation than NG12. The results add to the growing body of 
evidence supporting the use of FIT as the first-line investigation in in the assessment 
of patients presenting in primary (and secondary) care with lower GI symptoms, as 
recently argued.21 
There are now several studies including a meta-analysis that have evaluated the diagnostic 
performance of FIT in symptomatic and high-risk populations, suggesting high sensitivity and 
specificity for CRC.3, 7 A Spanish study of 787 patients referred for colonoscopy showed that 
FIT was more accurate in detecting CRC than the previous 2011 NICE or the SIGN referral 
criteria.6 Similar to the results observed in this study, they demonstrated that, in a high risk 
population, using a f-Hb cut-off of >20 µg Hb/g faeces, 20% fewer colonoscopies would have 
been required to detect 42% more CRC. A further study done in a different region of Spain 
confirmed these results: NICE and SIGN guidelines detected 46.7% and 43.3% of cases of 
CRC while f-Hb ≥15 μg Hb/g faeces detected 96.7% of cases.16 In other studies investigating 
the use of f-Hb for detection of CRC in symptomatic patients, sensitivity has ranged from 67% 
to 100% and specificity from 71% to 93% dependent on the f-Hb cut-off used.6, 15, 17-19 As in 
this study, inspection of the NPV in particular demonstrates that the results of these studies 
provide telling evidence that the f-Hb has the potential to be a good rule-out test for SCD and 
could therefore reduce the number of unnecessary referrals for colonoscopy, easing the 
pressure on already over-subscribed services. To allow comparison between studies, we used 
>10 µg Hb/g faeces as the f-Hb cut-off, exactly in keeping with latest draft NICE guideline in 
development (GID-DG10005) on quantitative faecal immunochemical tests to assess 
symptomatic people who are at low risk of colorectal cancer in primary care.21 
Limited data are available on the diagnostic accuracy of f-Hb for non-neoplastic SCD, 
particularly IBD. We have previously demonstrated that, in a population of symptomatic 
patients referred for endoscopy from primary care, CRC, HRA and IBD had significantly higher 
median f-Hb than those with less clinically important findings.17 Using a cut-off of >10 µg Hb/g 
faeces, the current study has demonstrated a sensitivity, specificity and PPV and NPV of f-Hb 
for CRC of 93.3% (95%CI: 80.7-98.3), 77.3 (95%CI: 75.1-79.4), 11.2% (95%CI: 8.3-14.9) and 
99.7% (95%CI: 99.2-99.9) respectively. 1283 (84.7%) of our patient cohort had non-significant 
colonic findings – normal bowel (933 patients; 61.6%), and less significant pathology such as 
haemorrhoids, hyperplastic polyps and simple diverticular disease (397 patients; 26.2%). 
Using f-Hb as a triage investigation in this cohort would potentially have avoided a referral and 
subsequent invasive investigations in the 82.2% of patients without serious pathology. NG12 
is concerned with the detection of lower GI cancer and therefore does not have such a 
broad clinical aim as the published concepts from Scotland on the application of f-Hb. 
As expected, f-Hb missed overall fewer cases of AN, IBD and SCD. However, in spite of 
missing some cases, the high NPV demonstrates that this approach of investigating all 
patients with lower GI symptoms with an initial f-Hb is most appropriate for use as a 
rule-out test for SCD, but with robust safety-netting procedures in place. This 
interpretation is in agreement with previous studies utilising FIT for assessment of 
symptomatic populations.2, 18, 19   
We observed that 229 patients (15.1%) who had f-Hb >10 µg Hb/g faeces had no significant 
pathology as compared with 603 (40.0%) patients referred following NG12 guidelines. The 
concern from clinical specialists that using f-Hb in primary care to triage suspected colorectal 
cancer referrals could result in unnecessary colonoscopy referrals is not confirmed by this 
study. In addition, the number of false-positive test results that occur when using f-Hb to 
diagnose CRC, as shown by the PPV, would be partially offset by detecting other important 
and treatable bowel diseases, particularly HRA and IBD. Positive FIT should be viewed as a 
marker of potential SCD, irrespective of symptoms. 
The strengths of this study include the large sample size, with 1514 patients providing age, 
sex, complete symptom data, as well as f-Hb and final diagnoses. In addition, the unselected 
nature of the patients referred from primary care increases the applicability of the findings to 
those working to identify cases of SCD in primary and secondary care.  A limitation of our 
study is that the location of the CRC and HRA was not recorded and therefore cannot be 
assessed in terms of predictive value of disease detection. This will be very interesting to 
study further if f-Hb is rolled out into routine clinical practice, as will studies on the 
health economic benefits of introducing this test and potential cost savings through 
reduction in referrals and number of colonoscopic (and possibly imaging) procedures 
undertaken.  A further limitation is that it might be considered invalid to evaluate referral 
criteria in referred patients only.  The NG12 guidelines were unavailable when these 
studies were done: interestingly, the Scottish referral guidelines for suspected cancer23 
are much less prescriptive than NG12, but f-Hb is now seen to have significant potential 
as the first-line investigation in assessment of patients presenting in primary care with 
lower abdominal sysmptoms.24 
In conclusion, we have demonstrated that, in the primary care setting, the reliability of f-
Hb to rule-out most SCD is high and we believe that our results are widely applicable. 
In addition, f-Hb has significantly higher overall diagnostic accuracy than NG12 referral 
criteria for CRC detection. Although we do not have any data on the acceptability of FIT to 
patients presenting in primary care with lower GI symptoms, the need for only one faecal 
sample, collected in an easy to use, hygienic device, should encourage completion of the test. 
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 Table 1. Summary of NICE NG12 guidelines for suspected gastrointestinal cancer and 
number of study participants fulfilling the individual criteria for referral 
 
Criteria 
Number  (%) of study 
participants satisfying 
criteria 
Refer adults using a 
suspected cancer pathway 
referral (for an appointment 
within 2weeks) for 
colorectal cancer if: 
They are aged 40 and over 
with unexplained weight loss and 
abdominal pain or 
14 (0.9) 
They are aged 50 and over with 
unexplained rectal bleeding or 313 (21.7) 
They are aged 60 and over with: iron 
deficiency anaemia or changes in 
their bowel habit or tests show 
occult blood in their faeces. 
371 (24.5) 
Consider a suspected cancer 
pathway referral for 
colorectal cancer in adults 
with 
Rectal or abdominal mass 0 (0) 
Consider a suspected cancer 
pathway referral for 
colorectal cancer in adults 
aged under 50 with rectal 
bleeding and any of the 
following unexplained 
symptoms or findings: 
Abdominal pain 13 (0.9) 
Change in bowel habit 18 (1.2) 
Weight loss 1 (0.1) 
Iron deficiency anaemia 1 (0.1) 
Offer testing for occult 
blood in faeces to assess for 
colorectal cancer in adults 
without rectal bleeding 
who: 
Are aged 50 or over with 
unexplained abdominal pain or 
weight loss or 
220 (14.5) 
Over aged 60 with: changes in their 
bowels or iron deficiency anaemia or 183 (12.1) 
Are aged 60 and over and have 
anaemia even in the absence of iron 
deficiency. 
82 (5.4) 
 
 
 
  
Table 2. Comparison of overall diagnostic accuracy assessed by the Area under the 
Receiver Operating Characteristic Curve (AUC), with 95% CI, for faecal haemoglobin 
concentration, overall, and by FIT analyser and study, and for the NICE NG12 guidelines for 
colorectal cancer 
 Faecal haemoglobin concentration  
NICE NG12 Disease Overall OC-Sensor 
Diana (FITS) 
HM-JACKarc 
(FITS2) 
OC-Sensor io 
(FITS+) 
Colorectal 
cancer (CRC) 
0.85 (0.87-0.90) 0.87 (0.78-0.94) 0.89 (0.84-0.93) 0.84 (0.77-0.91) 0.65 (0.58-0.73) 
Higher risk 
adenoma 
(HRA) 
0.64 (0.56-0.70) 0.72 (0.62-0.82) 0.65 (0.51-0.78) 0.59 (0.50-0.67) 0.54 (0.47-0.60) 
All neoplasia 
(CRC + HRA) 
0.72 (0.67-0.77) 0.76 (0.67-0.85) 0.74 (0.64-0.84) 0.69 (0.62-0.82) 0.58 (0.53-0.63) 
Inflammatory 
bowel 
disease (IBD) 
0.70 (0.64-0.76) 0.63 (0.52-0.75) 0.69 (0.57-0.81) 0.74 (0.65-0.82) 0.52 (0.46-0.59) 
Significant 
colorectal 
disease (CRC 
+ HRA + IBD) 
0.73 (0.69-0.77) 0.73 (0.65-0.81) 0.73 (0.65-0.81) 0.73 (0.67-0.78) 0.56 (0.52-0.60) 
 
 
  
Table 3. Sensitivity, specificity, positive predictive value (PPV), negative predictive value 
(NPV), as percentages, and area under the ROC curve (AUC), with 95% CI, of faecal 
haemoglobin concentration (f-Hb) overall and by sex and age, using a cut-off of >10 µg 
Hb/g faeces. 
  f-Hb  Overall Male Female <50 years >50 years 
Colorectal 
cancer (CRC) 
Sensitivity  93.3% (80.7-98.3) 100.0% (82.2-1.0) 88.0% (67.7-96.8) 100.0% (31.0-1.0) 92.9 (79.4-98.1) 
Specificity  77.3% (75.1-79.4) 73.0% (69.3-76.3) 80.7% (77.8-83.3) 79.8% (75.0-84.1) 76.6% (73.5-78.6) 
PPV  11.2% (8.3-14.9) 11.8% (7.8-17.4) 12.0% (7.8-17.8) 4.5% (1.2-13.4) 12.7% (9.0-16.7) 
NPV 99.7% (99.2-99.9) 100.0% (99.0-1.0) 99.6% (98.6-99.9) 100.0% (98.1-1.0) 99.7% (96.0-98.3) 
AUC 0.85 (0.87-0.90) 0.86 (0.83-0.90) 0.84 (0.75-0.92) 0.90 (0.83-0.97) 0.85 (0.80-0.90) 
Higher-risk 
adenoma 
(HRA) 
Sensitivity 50.5%  (40.1-60.9) 56.6% (42.4-69.9) 42.9% (28.1-58.9) 57.1% (29.6-81.2) 49.4% (38.1-60.6) 
Specificity 77.0% (74.7-79.1) 72.8% (69.0-76.2) 80.1% (77.1-82.7) 80.8% (75.8-83.4) 75.9% (73.2-78.4) 
PPV  12.8% (9.7-16.7) 15.4% (10.7-21.4) 10.0% (6.2-15.6) 11.9% (5.7-22.7) 13.0% (9.5-17.4) 
NPV  95.9% (94.5-96.9)  95.0% (92.5-96.7) 96.4% (94.7-97.6) 97.6% (94.7-99.0) 95.4% (93.7-96.6) 
AUC 0.64 (0.56-0.70) 0.65 (0.57-0.73) 0.62 (0.52-0.71) 0.69 (0.53-0.85) 0.62 (0.56-0.69) 
All neoplasia 
(CRC + HRA) 
Sensitivity 64.3% (55.7-72.1) 69.7% (58.0-79.4) 59.7% (47.0-71.3) 64.7% (38.6-84.7) 64.2% (55.0-72.5) 
Specificity 79.3% (77.0-81.3) 75.6% (71.9-79.0) 81.9% (79.0-84.5) 81.6% (76.7-85.7) 78.6% (76.0-81.0) 
PPV  24.0% (19.8-28.7) 27.2% (21.2-34.1) 21.9% (16.2-28.7) 16.4 (8.9-27.9) 25.7% (20.9-31.0) 
NPV 95.6% (94.2-96.7) 95.0% (92.5-96.8) 96.0% (94.1-97.3) 97.6% (94.7-99.0) 95.3% (93.3-96.3) 
AUC 0.72 (0.67-0.77) 0.73 (0.66-0.79) 0.70 (0.63-0.77) 0.73 (0.60-0.87) 0.71 (0.66-0.77) 
Inflammatory 
bowel 
disease (IBD) 
Sensitivity  61.5% (50.7-71.4) 66.7% (50.9-79.6) 56.5% (41.2-70.7) 60.0% (40.7-76.8) 62.3% (48.9-74.1) 
Specificity  77.6% (75.3-79.7) 73.1% (69.4-76.6) 81.0% (78.0-83.6 83.2% (78.2-87.2) 76.2% (73.5-78.6) 
PPV 14.9% (11.6-19.0) 15.4% (10.8-21.4) 14.4% (9.8-20.6) 26.9% (17.1-39.3) 12.3% (9.0-16.6) 
NPV 96.9% (95.7-97.8) 96.8% (94.6-98.1) 97.0% (95.4-98.1) 95.3% (91.7-97.4) 97.4% (96.0-98.3) 
AUC 0.70 (0.64-0.76) 0.70 (0.62-0.78) 0.69 (0.60-0.77) 0.72 (0.61-0.82) 0.69 (0.62-0.77) 
Significant 
colorectal 
disease (CRC 
+ HRA + IBD) 
Sensitivity 63.2% (56.6-69.4) 68.6% (91.4-94.4) 57.3% (47.5-66.5) 61.7% (46.4-75.1) 63.6% (56.1-70.4) 
Specificity 83.3% (81.1-85.2) 79.2% (75.4-82.5) 84.3% (81.4-86.8) 86.1% (81.3-90.0) 81.1% (78.4-83.4) 
PPV 38.9% (34.0-44.1) 42.6% (35.6-49.8) 35.0% (28.1-42.5) 43.3% (31.4-55.9) 38.0% (32.6-43.6) 
NPV 93.1% (91.4-94.4) 91.8% (88.8-94.1) 93.0% (28.1-42.5) 92.9% (88.8-95.6) 92.4% (90.4-94.0) 
AUC 0.73 (0.69-0.77) 0.74 (0.69-0.79) 0.71 (0.65-0.77) 0.74 (0.65-0.83) 0.72 (0.68-0.77) 
 
  
Table 4. Number of patients with colorectal diseases missed using faecal haemoglobin 
concentration at >10 µg Hb/g faeces cut-off and number missed using NICE NG12 
guidelines 
 
Disease No missed using faecal 
haemoglobin concentration 
at 10 µg Hb/g faeces cut-off 
No missed using NICE NG12 
guidelines 
Colorectal cancer 
(CRC) 
3 10 
Higher risk 
adenoma (HRA) 
47 43 
All neoplasia 
(CRC + HRA) 
50 53 
Inflammatory 
bowel disease 
(IBD) 
35 43 
Significant 
colorectal 
disease (CRC + 
HRA + IBD) 
85 96 
 
